TSHA 8-K: Q2 2025 Results Furnished via Press Release; XBRL Attached

Rhea-AI Filing Summary

Taysha Gene Therapies disclosed that it furnished a press release reporting financial results and business highlights for the quarter ended June 30, 2025. The filing states the press release is included as Exhibit 99.1 and that the cover page interactive XBRL file is provided as Exhibit 104. The company notes the information in Item 2.02 (including Exhibit 99.1) is being furnished and is not deemed "filed" for purposes of Section 18 of the Exchange Act.

This report identifies the exhibits attached but does not present the detailed financial figures within the body of the 8-K itself; investors should consult Exhibit 99.1 for the full results and disclosures.

Positive

• Press release furnished reporting the quarter ended June 30, 2025, is attached as Exhibit 99.1
• Interactive XBRL cover page (Exhibit 104) is included with the filing
• Filing follows standard 8-K practice by furnishing results via press release and referencing exhibits

Negative

• No detailed financial figures are presented in the 8-K text provided here; readers must consult Exhibit 99.1 for results
• Information is "furnished," not "filed," limiting Section 18 liability but meaning the filing body lacks standalone financial disclosure

Insights

Financial Analyst

TL;DR: Routine earnings disclosure furnished via press release; no financial detail appears in the 8-K text provided here.

The company furnished a press release reporting results for the quarter ended June 30, 2025, and included an inline XBRL cover page. Because the filing explicitly treats the release as "furnished" rather than "filed," legal liability under Section 18 is limited. The material substance (actual revenue, earnings, cash position) is contained in Exhibit 99.1, which must be reviewed to assess financial performance and valuation impact.

Corporate Governance Expert

TL;DR: Disclosure procedure follows standard practice; exhibits are properly referenced but the 8-K body is limited in substance.

The Form 8-K references Exhibit 99.1 for results and Exhibit 104 for interactive XBRL tags, which is consistent with regulatory disclosure norms. The filing clarifies the press release is furnished and not filed, preserving the registrant's Section 18 protections. For governance and compliance review, the presence of XBRL tagging is positive, but the actual content of Exhibit 99.1 should be examined to confirm completeness and materiality of the financial disclosures.

false 0001806310 0001806310 2025-08-12 2025-08-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

Taysha Gene Therapies, Inc.

(Exact name of registrant as specified in its Charter)

Delaware		001-39536		84-3199512
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3000 Pegasus Park Drive, Suite 1430 Dallas, Texas		75247
(Address of Principal Executive Offices)		(Zip Code)

(214) 612-0000

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.00001 par value		TSHA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2025, Taysha Gene Therapies, Inc. reported financial results and business highlights for the quarter ended June 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference.

The information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated August 12, 2025.
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Taysha Gene Therapies, Inc.
Dated: August 12, 2025				By:		/s/ Kamran Alam
						Kamran Alam
						Chief Financial Officer

FAQ

What did TSHA report in this 8-K?

The company furnished a press release reporting financial results and business highlights for the quarter ended June 30, 2025, attached as Exhibit 99.1.

Is the press release in this Form 8-K considered filed or furnished?

The company states the press release (including Exhibit 99.1) is furnished and not deemed "filed" under Section 18 of the Exchange Act.

Where can investors find the detailed financial results for TSHA?

Detailed results and business highlights are in Exhibit 99.1 to this Form 8-K; the 8-K text references the exhibit but does not include the full financial figures.

Does the filing include XBRL data for TSHA?

Yes. The cover page interactive data file (inline XBRL) is included as Exhibit 104.

Who signed the Form 8-K for Taysha (TSHA)?

The filing is signed on behalf of the registrant by Kamran Alam, Chief Financial Officer.